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Abstract
Idiopathic pulmonary fibrosis (IPF) is likely to result from the interaction between environmental
exposures, including cigarette smoke, and genetic predisposition. This review focuses on clues provided by
recent genetic association studies andother selecteddata andhypotheses. In IPF, associationwith surfactant
mutations has highlighted the importance of type II epithelial cells, while shortened telomeres in some
patients suggest that accelerated aging may play a role in the pathogenesis of lung fibrosis, possibly by
affecting the renewal/differentiation potential of epithelial cells. The finding that a common variant in mucin
5B predisposes individuals to both familial and sporadic IPF suggests a hitherto under-investigated role of
bronchiolar cells and mucins. Although the pathogenetic link between mucins and lung fibrosis is not
known, it is possible that MUC5B overexpression interferes with physiological mucosal host defense, with
reduced clearance of micro-organisms or inorganic noxious agents, or induction of endoplasmic reticulum
stress. Other components of innate and adaptive immunity are likely to be involved in IPF pathogenesis/
progression. Finally, the importance of the clotting cascade in IPF pathogenesis has been confirmed by a
recent epidemiological study, in which patients with IPF were almost five times more likely than general
population controls to have at least one inherited or acquired clotting defect.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive
fibrotic disease limited to the lungs, occurring in older
individuals, more frequently men, and characterized
by a dismal prognosis, with a median survival of 3 to
5 years since diagnosis, although a wide variability in
disease course is increasingly recognized. According to
the more commonly held and current pathogenetic
model, IPF results from recurrent injury to epithelial
cells caused by a variety of exposures. These include
cigarette smoke, dusts, and other environmental agents,
which, in a genetically predisposed individual, lead
to activation of abnormal pathways, resulting in failed
resolution of the wound-healing response. This article
does not aim to provide an exhaustive review of
pathogenetic pathways in IPF, but rather will focus on
selected topics, in particular on contributions to the
understanding of IPF pathogenesis provided by recent
genetic association studies, and other selected data and
hypotheses.
Genetic studies
Genetic predisposition to IPF is supported by familial
clustering, the occurrence of lung fibrosis in genetic multi-
system disorders, and differing susceptibilities in humans
exposed to similar levels of fibrogenic agents. Genetic
association studies are useful in identifying relevant
molecules/cell types among the wide array of potential
pathogenetic pathways and can highlight otherwise
unexpected areas.
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The role of type II cells
Mutations in the genes for surfactant protein C (SFTPC)
and surfactant protein A2 (SFTPA2) have been described
in association with familial lung fibrosis [1,2] and rarely
with sporadic IPF [3,4]. Although they account for only
approximately 1% of familial cases, the fact that both
surfactant proteins are exclusively synthesized by type II
alveolar epithelial cells points to type II cell dysfunction
as a key element in IPF. The relevance of type II cells is
also suggested by the prognostic value of serum
surfactant proteins in sporadic IPF and other interstitial
lung diseases (ILDs) [5]. In addition to synthesizing
surfactant proteins, type II alveolar cells are responsible
for the constant regeneration of the alveolar epithelium,
as precursors of the terminally differentiated type I cells.
Surfactant protein C and A mutations have been shown
to cause incorrect protein folding/processing, thereby
activating the cell’s endoplasmic reticulum (ER) stress
response. This is a stereotypical protective mechanism in
response to the accumulation of misfolded proteins,
ultimately leading to activation of apoptosis pathways
[6,7]. Increased staining for markers of ER stress response
and apoptosis is also observed in sporadic IPF [8,9],
highlighting a prominent role for activation of the ER
stress response and alveolar cell apoptosis in pathogenesis.
Type II cells are also affected in the Hermansky-Pudlak
syndrome (HPS), a genetic disease frequently associated
with lung fibrosis. HPS is caused by mutations in genes
encoding for proteins involved in lysosome-related
intracellular trafficking, leading to giant lamellar body
formation in type II alveolar cells [10]. Although alveolar
epithelial ER stress has been described in HPS lung
fibrosis [11], Young and colleagues report that impaired
intracellular trafficking pathways do not directly result in
ER stress, suggesting further studies are needed to
evaluate mechanisms [12].
Telomere shortening
Pulmonary fibrosis occurs in a subset of patients with
dyskeratosis congenita, a rare genetic disorder. Rapidly
dividing tissues are affected, including epithelial cells and
bone marrow, secondary to mutations in genes encod-
ing for telomerase enzyme components. Telomerases
are responsible for the elongation of telomeres, repetitive
DNA sequences capping chromosome ends. Telomeres
shorten at each cell replication until a critical length is
reached, triggering a DNA damage response, leading to
cellular senescence or apoptosis. Loss of telomerase
activity reduces the renewal potential of stem cell
populations [13]. Rare mutations in the telomerase
genes TERT and TERC have been identified in approxi-
mately 8% of familial cases and in 1% to 3% of sporadic
cases [14,15]. Telomeres shorten with age, and telomere
dysfunction may be involved in a number of age-related
degenerative disorders [16]. Even in the absence of TERT/
TERC mutations, a proportion of IPF patients have
shorter telomeres compared with age-matched controls
[17,18]. In aggregate, these findings suggest that IPF may
be a disease of accelerated aging in the lung, at least in the
subset characterized by shortened telomeres. However,
shorter telomeres in circulating leukocytes compared with
age-matched control populations are also observed in
chronicobstructive pulmonarydisease (COPD), in asthma,
and in association with lower lung function in control
individuals, suggesting that the phenomenon of premature
aging is not specific to pulmonary fibrosis [19].
The mechanisms through which telomere/telomerase
defects may lead to pulmonary fibrosis are not well
known. As telomerase dysfunction is most likely to affect
cells with high turnover, epithelial cells are obvious
candidates. Indeed, IPF alveolar epithelium had shorter
telomeres than normal control epithelium, indepen-
dently of detectable telomerase mutations in one study
[17], although further studies are needed to confirm this
interesting observation. Telomerase activity may differ
according to cell type as increased telomerase activity has
been reported in IPF lung fibroblasts, which is in keeping
with potential increased survival and resistance to
apoptosis in these cells [20].
Bronchiolar cells
A prominent role for activated bronchiolar-type epithelial
cellswas first proposedbyChilosi and colleagues, in a study
reporting activation of the Wnt/beta-catenin/matrylisin
developmental pathway in hyperplastic bronchiolar lesions
[21]. This was a feature seen in IPF but not in other ILD
patterns, in contrast with nuclear beta-catenin expression
observed in type II pneumocytes across ILDs. A particularly
strong beta-catenin staining in areas of bronchiolization
was confirmed by Konigshoff and colleagues [22].
In genetic studies, a role for bronchiolar cells has been
suggested by the finding of a marked increase in aMUC5B
gene common promoter polymorphism in familial
interstitial pneumonia (FIP) and sporadic IPF compared
with controls (minor allele present in 33.8% of FIP cases,
37.5% of sporadic IPF cases, and 9.1% of control subjects)
[23,24]. This strong association suggests the pathogenetic
significance of mucins/small airways in IPF. By contrast,
no association was found between MUC5B and scler-
oderma-associated lung fibrosis or with fibrotic sarcoido-
sis, suggesting that this association may be specific to the
idiopathic ILDs [25,26].
Although the MUC5B variants are associated with
overexpression in lung tissue compared with non-carriers
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in control subjects, this is not the case in IPF, where lung
MUC5B overexpression is seen independently of genetic
variants [23]. This observation suggests that, in the
absence of (or in addition to) MUC5B genetic variation,
other environmental or genetic factors (or both) linked
to disease pathogenesis cause its upregulation. MUC5B
appears to localize mainly to the distal airways and to the
honeycomb cysts in what appear to be bronchiolar cells
rather than type II alveolar cells [27]. Honeycombing
lesions would therefore derive from the dilatation of the
small airways, an observation that was originally made
more than 50 years ago [28]. The mucin-producing cells
in the honeycombed areas are characterized by a tran-
scription factor and mucin profile suggestive of abnor-
mal programming, with a phenotype similar to that of
submucosal gland goblet cells, normally not found in
the distal airspaces [29]. The mechanism by which
MUC5B polymorphisms predispose individuals to pul-
monary fibrosis is not known. One of the hypotheses is
that MUC5B variants may lead to impaired clearance of
inhaled micro-organisms and other particles and there-
fore an aberrant innate response, although a direct toxic
effect on epithelial cells and/or ectopic expression with
intracellular accumulation and resulting ER stress
response are also possibilities [23,30].
Interestingly, while MUC5B overexpression is associated
with IPF independently of the genetic polymorphisms,
the MUC5B genetic variant actually appears to be asso-
ciated with slower progression and better survival [26,31],
suggesting that it marks a subset of the disease. There is a
known variability in the clinical course of IPF, ran-
ging from prolonged stability/gradual worsening to rapid
stepwise progression [32–34]. Disease subsets are also
suggested by a recentwhole-genome expression analysis in
a large number of IPF biopsies [35]. Clustering of the genes
differentially expressed compared with controls reveals a
separation into two clear IPF subpopulations, based on a
distinct molecular signature. One IPF group is character-
ized by overexpression (compared with the other) of a
number of genes already known to be upregulated in
IPF, including osteopontin, matrix metalloprotease
1 (MMP1), MMP7, and MUC5B. The same IPF group is
also characterized by upregulation of a large number of
transcripts associated with cilium genes. These include
structural components such as axonemal dyneins involved
in ciliary motility as well as transcription factors regulating
cilium gene expression, including RFX3, FOXJ1, and RFX2.
Patients with high cilium gene expression demonstrate
more microscopic honeycombing but not more fibro-
blastic foci on lung biopsy [35]. These observations re-
inforce the role played by airway cells (at least in a subset)
and for the first time provide molecular evidence that IPF
may in fact consist of more than one disease, each with
likely different pathogenesis, prognosis, and treatment
responses. The authors do not mention whether these two
subsets separate out according to theMUC5B polymorph-
isms or whether they are characterized by different
longitudinal behavior, and no doubt further studies will
shed light on this.
Two recent large genome-wide case-control association
studies have confirmed the association with MUC5B
[36,37], with the study by Fingerlin and colleagues [36]
also identifying associations with common variants in the
TERT and TERC genes. Both studies also report associa-
tions with several novel common gene variants. Among
these, Fingerlin and colleagues report an association with
genes involved in epithelial integrity and cell-cell adhe-
sion, including desmoplakin (DSP) and DPP9, suggesting
that defects in cell-cell adhesion or cellular cytoskeleton
(or both) could predispose patients to injury in response
to stimuli, including mechanical stretch. Both studies
report an association with TOLLIP, a regulator of innate
immune responses involved in modulating Toll-like
receptor (TLR) signaling. The TOLLIP gene resides close
to MUC5B, and variants in the two genes are in weak
linkage disequilibrium. Once the MUC5B variants were
included in the analysis, the association with the TOLLIP
gene single-nucleotide polymorphisms (SNPs) only just
reached statistical significance in the study by Noth and
colleagues [37] (P = 0.05) and was no longer significant in
the study by Fingerlin and colleagues, indicating the need
for further studies. Interestingly, the minor allele of one of
the TOLLIP SNPs (rs5743890) found to be protective
toward lung fibrosis was associated with worse survival.
This finding was maintained on adjusting for other gene
variants, although MUC5B was not included in the
multivariate analysis [37]. Again, whether the TOLLIP
variant is a prognostic determinant, independently of
MUC5B, remains to be determined.
Gene expression and epigenetic regulation
Transcriptional profiling studies of fibrotic lung tissues
have identified key differences with control tissues and
between different fibrotic ILD patterns [38–41]. Matrily-
sin (MMP7), one of the downstream targets of Wnt/beta-
catenin, is highly overexpressed in IPF biopsies [38] and
has been investigated as a peripheral blood biomarker in
ILD. In the largest prospective biomarker study per-
formed so far in IPF, MMP7, together with intercellular
adhesion molecule-1 (ICAM-1) and interleukin-8 (IL-8),
was the strongest predictor of survival in combination
with clinical characteristics [42]. Boon and colleagues
reported on upregulation in pathways involved in cell
growth, proliferation, and migration in lung tissue from
rapidly progressive compared with relatively stable IPF
[43], suggesting that there may be common pathways
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between lung fibrosis and cancer development [44].
Rapidly progressive fibrosis was also characterized by
upregulation of PLUNC, a molecule expressed mainly by
secretory bronchial columnar cells, again highlighting a
potential role for airway/innate defense functions [43].
With regard to fibroblasts, these are the main effector cell
types involved in the fibrotic process [45], regardless of
the initiating triggers. Gene expression profiling studies
of cultured lung fibroblasts show specific pathways of
activation [46–48], which appear to be similar in IPF and
in scleroderma-associated ILD [48].
Although the study of epigenetic regulation in IPF is
relatively recent, analysis in lung tissue or in IPF
fibroblasts (or both) of the global and individual gene
expression regulation through methylation [49–51],
acetylation [52,53], and regulatory microRNAs [54–61]
is providing information on regulatory networks and
should allow a better understanding of how particular
genetic variants and environmental exposures interact to
cause pulmonary fibrosis, ultimately leading to novel
treatment strategies.
Innate and adaptive immune responses
The role played by conventional inflammation in IPF
pathogenesis has been questioned, mainly in view of the
lack of response to corticosteroids and immunosuppres-
sants, which may indeed be harmful in patients with IPF
[62]. However, components of the innate and adaptive
immune response are thought to contribute to the
pathogenesis of lung fibrosis.
The innate immune systemplays a crucial role in initiating
and terminating inflammatory responses to endogenous
and exogenous noxious stimuli. The alveolar macrophage
is a potential source of chemokines and growth factors that
regulate the wound-healing response. Macrophages are
characterized by at least two phenotypes: M1, induced by
Th1 cytokines such as interferon, and expressing IL-12,
tumor necrosis factor (TNF), and C-X-C motif chemokine
(CXCL)10, and M2 (or alternatively activated M), which
expresses CD163, mannose receptors, and secretes
increased levels of IL-10, chemokine (C-C motif) ligand
(CCL)18, and CCL22 [63]. Two carefully conducted large
prospective studies have shown that bronchoalveolar
lavage (BAL) and serum levels of CCL18, one of the
markers of M2 macrophages, are significantly linked to
extent of fibrosis and predict likelihood of progression,
even after adjustment for disease severity, both in IPF and
in systemic sclerosis-ILD [64,65].
Pattern recognition receptors, including TLRs, recognize
pathogen and endogenous patterns, activate innate and
adaptive immune responses, and participate in regulating
wound healing [66]. Pathogen-associated molecular
patterns (PAMPs) are suspected to play a role in the
activation of fibroblasts through TLRs as well as nucleo-
tide-binding oligomerization domain-like receptors
(NLR)s and retinoic acid-inducible gene-1 (RIG-1)
receptors [67]. Endogenous ligands can also be identified
by TLRs, including components of the extracellular
matrix such as hyaluronic acid [68], and fibrinogen
degradation products [69]. Interestingly, the ligation of
the latter to TLR4 has been shown to induce upregulation
of mucin MUC5AC expression in both alveolar macro-
phages and epithelial cells [69].
TLR9 expression has been found to be increased in ILD
lung tissue and in IPF fibroblasts compared with control
subjects [70,71]. In particular, in both usual interstitial
pneumonia (UIP) and non-specific interstitial pneumo-
nia (NSIP), the increased expression is localized to areas
of fibrosis in the epithelium and interstitium [70]. TLR9
activation by hypomethylated DNA significantly
increased alpha smooth muscle actin [70] and promoted
profibrotic cytokine and chemokine synthesis in IPF
fibroblasts in culture [72]. TLR9 was particularly
upregulated in the lung tissues of rapidly progressive
IPF compared with more stable disease [73].
TLR3 has been shown to act as a sensor of tissue necrosis
during acute inflammation. In addition, it recognizes
virus-associated molecular patterns and activates pro-
inflammatory cascades [74,75]. Recently, a TLR3 poly-
morphism (TLR3L412F) associated with defective
function of the receptor was studied in patients with
IPF. Fibroblasts homozygous for the variant allele had
an impaired interferon-beta response, displaying
enhanced proliferation after TLR3 stimulation, partially
corrected after interferon-beta treatment. Furthermore, the
variant was associated with disease progression or early
mortality (or both) in two separate IPF cohorts, with an
additive effect for each allele [76]. This study is another
example of a genetic variant linked to outcome in IPF and
highlights the possibility of differences in response to
treatments in different subsets, as suggested by the
editorial accompanying the article [77]. The activation of
TLRs in epithelial and interstial cells could be one of the
links between exogenous/endogenous noxious signals
and amplification of immune and fibroproliferative
responses. Further studies are needed to assess their role
in the pathogenesis of pulmonary fibrosis.
Adaptive immunity is also likely to be involved in IPF
progression. We know that in hypersensitivity pneu-
monitis (HP) adaptive immunity is a crucial driver of
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disease. A proportion of patients with fibrotic HP have a
UIP histology and can display an IPF-like disease course
[78], although features such as airway centeredness of
fibrosis and excess inflammation suggest the diagnosis
of HP-associated UIP [79]. There may be at least a
subset of patients with IPF in whom the fibrotic
response is a response to an unknown antigen, with a
role played by adaptive immunity. Indeed, Gilani and
colleagues found that increased proportions of circulat-
ing CD28nullCD4+ T cells are associated with poor
outcomes in patients with IPF [80]. CD28nullCD4+ cells
are effector memory T cells, which develop as a result of
repeated antigen-driven proliferations. These cells display
increased production of cytotoxic mediators and pro-
inflammatory cytokines, in keeping with enhanced
noxious potential. Interestingly, CD28null T-cell telomeres
are shortened as a result of repetitive T-cell clonal
proliferations [81], and T cells comprise 40% to 50% of
peripheral blood monocytes. This could contribute to
findings of telomere shortening in the peripheral blood
leukocytes of IPF patients and other populations with
chronic disease. The relevance of T-cell differentiation in
IPF, again as a result of repetitive antigen stimulation, is
also supported by a recent report by Herazo-Maya and
colleagues [82]. BAL and lung tissue-activated CD4+ T cells
are observed in asymptomatic early familial ILD cases
[83], and pro-inflammatory dendritic cells are found
in advanced lung fibrosis [84]. In IPF lungs, CD8+
T lymphocytes correlated with degree of breathlessness
and functional severity [85]. IPF lung-derived proteins
induce proliferation of autologous CD4 T cells from these
patients [86]. Semaphorin 7a+ regulatory T cells are
increased in the blood of patients with rapidly progressive
IPF [87].
In addition to T cells, B cells may also be involved in IPF
pathogenesis. Auto-antibodies against heat shock protein
70 (HSP 70) are associated with short-term deterioration
in patients with IPF, independently of disease severity,
suggesting a potential link to a pathogenetically sig-
nificant process [88]. The finding of lymphoid follicles in
IPF biopsies has been reported in a number of studies
[89-91]. The presence of B-cell aggregates in injured
tissues suggests a possible direct contribution of the
significant pathogenetic potential of B cells to the fibrotic
process [92]. Xue and colleagues observed an increase in
circulating antigen-differentiated plasma cells in IPF
patients and overexpression of a specific B-cell trophic
factor (plasma B lymphocyte-stimulating factor), asso-
ciated with poor short-term outcome [90]. A chemokine
that mediates B-cell trafficking, CXCL13, was increased in
the lung tissue and peripheral blood of IPF patients
compared with healthy controls and COPD patients and
was predictive of early mortality, further supporting a
pathogenetic role for B cells [93].
It seems likely that both the innate and adaptive immune
systems participate in lung fibrosis progression. However,
the question of whether the hyperstimulation of the
immune system described above is directly causative of
lung fibrosis rather than a consequence of the loss of the
normal lung architecture and therefore of natural defenses
is more difficult to resolve. We should also consider the
possibility of an interaction between the different patho-
genetic mechanisms. For example, Agrawal and colleagues
recently observed that an interaction between surfactant
protein (SP)-A and TLR2 is involved in regulating secretion
of pro-inflammatory mediators in macrophage lines both
in vitro and in vivo [94].
The clotting cascade
The clotting cascade appears to be activated in
pulmonary fibrosis, as suggested by in vitro and animal
model studies [95]. Cleaved clotting factors have major
pro-inflammatory and profibrogenic effects [96], and
activated platelets/endothelial cells release fibrogenic
mediators, including platelet-derived growth factor
(PDGF) and transforming growth factor-beta (TGFb)
[97]. Navaratnam and colleagues recently reported on a
carefully conducted case-control study of 211 incident
IPF cases to evaluate the incidence of clotting abnorm-
alities identified through a pro-thrombotic panel of 11
clotting defects [98]. The authors found that patients
with IPF have an almost fivefold greater chance of
having at least one clotting abnormality, with incre-
mentally increasing odds ratios for increasing numbers
of clotting abnormalities. The highest odds ratios were
seen for elevation of factor VIII levels (>165 IU/dL in
124 out of 194 patients with IPF versus 45 out of 211
controls). Furthermore, clotting abnormalities were
associated with more severe disease at baseline and a
worse survival. How this fits with the recent trial of
warfarin treatment in IPF, which was stopped early
because of an increased rate of pulmonary fibrosis
deterioration in the warfarin-treated arm [99], will need
to be further investigated, but it does support previous
studies pointing to an important role played by the
coagulation system in the lung fibrosis process.
Physical factors
Leslie recently proposed a unifying hypothesis for IPF as a
disease of “recurrent stretch injury to the peripheral and
basal lung occurring over many years in predisposed
individuals” [100]. This theory attempts to reconcile a
number of unexplained features, including the predomi-
nantly basal and subpleural distribution, the progression
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of the disease toward the apical regions, and the finding
that fibroblastic foci are a continuum extending inward
from the pleural surface (fibroblastic reticulum) [101].
IPF would start in the basal and peripheral regions of the
lungs, where the alveoli are the smallest in the upright
and supine positions and are therefore more likely to
collapse in response to the tractional forces during
respiration, as also suggested by Galvin and colleagues
[102] and Dail [103]. Surfactant protein abnormalities
could lead to increased surface tension and greater
likelihood of alveolar collapse, while the reticular
network of fibroblastic foci would occur along stress
fractures/lines at the interface between the epithelium
and the mesenchymal cells. A vicious circle of increasing
alveolar surface tension causing further alveolar collapse
and subsequent enlargement of the alveolar ducts
leading to microscopic honeycombing would follow.
Carloni and colleagues applied a mathematical model to
verify whether the distribution of IPF lesions corresponds
to the areas of greatest mechanical tension [104]. If
these mechanical forces have a role in the origin or in the
progression of the disease, they should also influence
those cases with associated emphysema, which were
initially described more than 20 years ago [105] and
which only recently have attracted the attention of
researchers [106]. In these cases, one would expect a
lower traction in the basal zones because of reduced
elastic recoil of the upper parts of the lung.
Conclusion
In conclusion, genetic association studies suggest a pivotal
pathogenetic role played by abnormal regeneration/
differentiation potential of respiratory epithelial cells in
IPF (both alveolar and bronchiolar), which is likely to be
determined by the interaction between environmental
exposures such as cigarette smoke and gene variants,
including surfactant protein and telomerase genes. The
associationwithMUC5B suggests a role of airway epithelial
cells and mucins. Further studies on how molecular
phenotypes can be linked in to genetic data and to clinical,
radiological, and histological characteristics of the disease
will be crucial to predict clinical course and drive novel
treatments in IPF.
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